Avelumab
- Generic Name
- Avelumab
- Brand Names
- Bavencio
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1537032-82-8
- Unique Ingredient Identifier
- KXG2PJ551I
- Background
Avelumab is a human IgG1 lambda monoclonal antibody that binds programmed cell death ligand-1 (PD-L1) to block its interaction with its receptors found on T cells and antigen-presenting cells. Avelumab was first approved by the FDA on March 23, 2017. On September 18 and December 18 of the same year, it was also granted approval by EMA and Health Canada, res...
- Indication
Avelumab is indicated for the treatment of adults with metastatic Merkel cell carcinoma (MCC). In the US, it is also used in patients 12 years and older.
...
- Associated Conditions
- Advanced Renal Cell Carcinoma, Metastatic Urothelial Cancer, Locally advanced Urothelial Carcinoma, Metastatic Merkel Cell Carcinoma (MCC)
- Associated Therapies
- First Line Chemotherapy, Maintenance therapy
Palbociclib After CDK and Endocrine Therapy (PACE)
- Conditions
- Interventions
- First Posted Date
- 2017-05-10
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 220
- Registration Number
- NCT03147287
- Locations
- 🇺🇸
The University of Kansas Cancer Center, Westwood, Kansas, United States
🇺🇸Indiana University, Indianapolis, Indiana, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Phase II Study of Avelumab in Metastatic Gastronetro-pancreatic （GEP） Neuroendocrine Carcinoma （NEC, WHO Grade 3） as Second-line Treatment After Failing to Etoposide+Cisplatin: Integration of Genomic Analysis to Identify Predictive Molecular Subtypes
- First Posted Date
- 2017-05-10
- Last Posted Date
- 2019-12-30
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 14
- Registration Number
- NCT03147404
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Expanded Access to Avelumab for Treatment of Metastatic Merkel Cell Carcinoma (mMCC)
- Conditions
- First Posted Date
- 2017-03-24
- Last Posted Date
- 2019-10-09
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Registration Number
- NCT03089658
- Locations
- 🇫🇷
Avelumab ATU Unit, Lyon, France
A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy
- First Posted Date
- 2017-03-10
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 60
- Registration Number
- NCT03076554
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery
- Conditions
- Interventions
- First Posted Date
- 2017-03-08
- Last Posted Date
- 2022-04-29
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 35
- Registration Number
- NCT03074318
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004
- First Posted Date
- 2017-02-13
- Last Posted Date
- 2021-12-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT03050814
- Locations
- 🇺🇸
Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States
🇺🇸National Institutes of Health Clinical Center, Bethesda, Maryland, United States
SBRT Combined With Avelumab (Anti-PD-L1) for Management of Early Stage Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2017-02-13
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Andrew Sharabi
- Target Recruit Count
- 2
- Registration Number
- NCT03050554
- Locations
- 🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸Sanford Health, Sioux Falls, South Dakota, United States
Avelumab in Relapsed and Refractory Peripheral T-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2017-02-08
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- University of Birmingham
- Target Recruit Count
- 35
- Registration Number
- NCT03046953
- Locations
- 🇬🇧
University College London Hospital, London, United Kingdom
Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2017-01-30
- Last Posted Date
- 2022-02-15
- Lead Sponsor
- Guru Sonpavde
- Registration Number
- NCT03035630
- Locations
- 🇺🇸
University of Alabama Hematology Oncology Clinic at Medical West, Birmingham, Alabama, United States
A Phase II Trial of Avelumab in Patients With Recurrent or Progressive Osteosarcoma
- First Posted Date
- 2016-12-30
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 19
- Registration Number
- NCT03006848
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸St Jude Children's Research Hospital, Memphis, Tennessee, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.